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INTRODUCTION
The standard approach for the treatment of advanced or disseminated cancer involves the systemic administration of antiproliferative cytotoxic agents. The major drawback to the nonselectivity of these agents against cancer is dose-limiting toxicity, with the consequent impact upon therapeutic efficacy. Over the past decade, in reflection of these limitations, a profound change in the direction for cancer drug development has evolved. Based upon the acquisition of addiction to specific oncogenic signaling pathways, approaches are now focused toward inhibition of specific dysregulated molecular pathways involved in cancer development and progression 1, 2 . In principle 'molecularly targeted' agents are highly selective agents against growth and survival of tumor cells, whilst sparing normal cells. However, despite improved treatment success and reduced toxicity relative to conventional cytotoxic chemotherapeutics, these approaches are not devoid of problems. It is becoming evident that efficacy of these such agents is hindered by genetic instability and heterogeneity within the cancer cell population, resulting in acquired drug resistance 3 . Furthermore, on-and off-target activities of many of these agents against particular 'normal' cell populations has led to induction of specific toxicities and detrimental physiological effects, and subsequent sub-therapeutic drug concentrations in the tumor [2] [3] [4] . Therefore the development of new therapeutics to circumvent these issues, with improved tumor selectivity, lower systemic toxicity, and limited potential for drug resistance is an important trajectory for improved cancer treatment.
One strategy is to develop agents targeting the tumor phenotype rather than intracellular signaling pathways, such as the tumor supporting vasculature or increased proteolytic activity of tumors [5] [6] [7] [8] [9] [10] . The selective disruption of the established blood supply to tumors is now known to be an effective therapeutic strategy, with several vascular disrupting agents (VDAs) currently in late stage clinical trial [11] [12] [13] [14] . The majority of these agents bind to the colchicinebinding domain of β-tubulin causing microtubule depolymerisation and consequent 4 morphological changes within endothelial cells 15 . The advantages of VDAs over other cancer therapeutics are that they are not required to extravasate from the blood vessel and penetrate across several cell layers for their activity, they avoid undesirable acquired drug resistance, and they target a fundamental process for survival of all solid tumors [11] [12] [13] . Furthermore, it is now well established that the disruption of a single tumor blood vessel results in death of the large number of tumor cells it supports 11, 13, 14 . Additionally, the destabilization of the tumor endothelium leads to a temporal enhancement of vascular permeability and consequent drug retention, with significant potential for therapeutic enhancement [14] [15] [16] . However, it is becoming increasingly apparent that the significant therapeutic value for these colchicine-related VDAs is compromised by their intrinsic toxicity, particularly cardiac toxicities 17, 18 . Therefore, strategies to reduce systemic exposure, increase tumor-selectivity and improve their therapeutic index are required.
Another fundamental issue which impacts upon the success of several current small molecule cancer therapies is their limited ability to localize at the tumor site. Many cytotoxic drugs demonstrate poor biodistribution in vivo, with tumor doses for common agents such as doxorubicin and paclitaxel reported to be around 5-10% of the dose accumulating in healthy organs 19, 20 . In addition to reduced efficacy, this also has implications for intrinsic systemic toxicity. Therefore, there is a considerable requirement for the development of a new generation of anticancer agents, capable of selective localization at the tumor and with reduced potential for systemic toxicity. One approach which addresses this need is the development of nanotherapeutic agents as tumor-targeted prodrugs, recently termed "cancer smartbombs" or "molecular grenades" 6 , whereby the potent therapeutic entity is masked until being activated by exploitation of unique phenotypic differences present in the tumor environment 6, 21, 22 .
Harnessing enzymes with elevated or specific activity within the tumor environment to convert a non-toxic prodrug into a potent anticancer agent is one approach with significant therapeutic scope 6, 8, 21, 23, 24 . A class of enzyme heavily implicated in cancer expansion and dissemination, and with clear applicability for prodrug development, are the proteolytic enzymes of the tumor degradome 21 . This strategy was recently exemplified through use of the tumor-endothelial expressed carboxypeptidase prostate-specific membrane antigen (PSMA)
for activation of the non-selective toxin thapsigargin, a successful approach which has now progressed to phase II clinical trial 6, 7 . Another family of enzymes within the tumor degradome with demonstrated potential for tumor-selective prodrug development are the matrix metalloproteinases (MMPs) 21 , particularly the membrane-type MMP (MT-MMP)
subfamily. Of these, the prototypic member MMP-14 (MT1-MMP) has the majority of required traits as a prodrug activating target; being pivotal for tumor invasive behavior and tumor vascularization [25] [26] [27] [28] [29] [30] , presenting as a direct target in the tumor vasculature for prodrug activation [25] [26] [27] 29 , and having the ability to selectively cleave specific peptide sequences 5, 31 .
Based on this, we previously designed a MMP-14-targeted nanotherapeutic prodrug, ICT2588, comprising the potent VDA, azademethylcolchicine, inactivated through conjugation to a cleavable peptide, which was endcapped to prevent non-specific exopeptidase degradation ( Figure 1 ) 5, 32 . The peptide sequence integral to this nanotherapeutic approach had been rationally developed to be selectively cleaved by MMP-14 5, 32 . The therapeutic strategy for ICT2588 involves hydrolysis by MMP-14 followed by subsequent nonspecific exopeptidase activity to produce azademethylcolchicine selectively within the tumor environment 5, 33 . This mechanism was supported in both ex vivo and in vivo studies through demonstration of MMP-dependent hydrolysis of ICT2588 followed by rapid production of active azademethylcolchicine, with no intermediate peptide-conjugated metabolites of ICT2588 detected 5 . In this study we have further evaluated the clinical 6 potential for this MMP-14 activated VDA strategy using a range of clinically relevant human solid tumor models and primary surgical samples. A reduced potential for drug-induced cardiovascular toxicity with ICT2588 was assessed by development of an assay to measure systemic levels of murine von Willebrand Factor (vWF), a validated biomarker of systemic vascular dysfunction and acute cardiovascular events [34] [35] [36] [37] .
EXPERIMENTAL SECTION

Synthesis of ICT2588
ICT2588 ( Figure 1 ) was synthesized and characterized in-house as a C-and N-terminal modified peptide conjugate of azademethylcolchicine (Figure 1 ), as previously described 32 .
For in vitro analyses, ICT2588 was prepared as a stock solution in dimethyl sulfoxide (DMSO). supernatants (equivalent to 100 mg tissue per ml). Over a 90 minute period, reaction aliquots were removed, proteins precipitated using acetonitrile and ICT2588 metabolism analyzed by LC-MS, as previously described 5 .
Determination of MT-MMP gene expression.
Assessment of MT-MMP gene expression as determined by quantitative real-time PCR
(qRT-PCR) was performed as previously described 38 . All primers and fluorogenic probe nucleotide sequences were synthesized by Applied Biosystems (Warrington, UK) and had been shown previously to be MMP gene specific 38, 39 . The 18S ribosomal RNA gene was used as an endogenous control to normalize for any difference in the amount of total RNA in each sample, using previously validated procedures 38, 39 . The C T (cycle at which amplification entered the exponential phase) was used as an indicator of the level of target RNA in each tissue, i.e. a lower C T indicated a higher quantity of target RNA. For data interpretation, results were normalized to calibrated curve data for the 18S-rRNA and MMP genes, as previously described 38, 39 .
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Determination of MMP-14 protein expression.
Tumor homogenates were prepared as previously described 5 . Equal amounts of protein (equivalent to 0.1mg xenograft tissue) were resolved by 10% SDS-PAGE and blotted onto
Hybond-P membrane (Amersham, UK). Non-specific antibody binding was blocked via incubation in 5% ECL blocking reagent (Amersham). The blot was probed with a monoclonal antibody to MT1-MMP (MAB3328; Chemicon International) overnight at 4C followed by a rabbit anti-mouse horseradish peroxidase (HRP)-conjugated antibody (Dako). Antibody reactivity was detected by chemiluminescence using ECL-Plus (Amersham).
Evaluation of Antitumor activity.
Female Throughout the study, all mice were housed in air-conditioned rooms in facilities approved by the Home Office to meet all current regulations and standards of the United Kingdom. All procedures were carried out under a United Kingdom Home Office Project License, following UK National Cancer Research Institute Guidelines for the Welfare of Animals (UKCCCR) guidelines 40 .
Measurement of systemic levels of von-Willebrand Factor (vWF)
Mice ( with correction at 550 nm, using a Multiskan EX platereader (Thermo Life Sciences). A calibration curve was generated using the vWF protein standards, and sample values were interpolated into this curve to obtain concentration values. Data were analyzed using SPSS, and mean differences considered statistically significant at the P < 0.05 level. Metabolites detected by LCMS and expressed as concentration of ICT2588 remaining.
RESULTS
Selective metabolism of ICT2588 in human clinical NSCLC relative to normal tissue
The elevated expression of MT-MMPs in non-small cell lung cancer (NSCLC) relative to associated normal lung tissue, and a strong correlation between MMP-14 gene expression and proteolytic activity is previously reported by our group 38 . In order for ICT2588 to be a viable clinical therapeutic option, it must show activation in tumor tissue, limited activation in nondiseased tissue and the potential for systemic pharmacological stability. Metabolism of ICT2588 was studied ex vivo using homogenates of two clinical samples of NSCLC and their respective blood plasma. In both tumor samples MMP-14 expression was elevated ( Figure   2A ) and ICT2588 was metabolized rapidly (t ½ = 11.4 minutes and 23.2 minutes, respectively ( Figure 2 ). In contrast, ICT2588 metabolism was minimal in plasma samples from these patients (t ½ > 90 minutes; Figure 2B ) and human and mouse liver homogenates ( Figure 2C ). In all tumor models, administration of the various treatments did not cause any significant loss in mouse body weight (≤15%; data not shown). 
Post-treatment changes in plasma vWF levels, as an indicator of cardiovascular effects.
Systemic levels of vWF were determined as an indicator of drug-induced detrimental effects upon the cardiovascular system, as previously reported [34] [35] [36] [37] . Using vWF standards the ELISA assay was linear between 2.0x10 -3 and 0.03 IU/ml (R 2 = 0.975), with an inter-assay variability of <5% (Data not shown). The dilution-corrected concentration of plasma vWF in vehicle-treated control mice was between 0.07 and 0.10 IU/ml monitored at 4, 24 and 48 hrs (Table 1) . This was comparable to that detected in non-treated mice plasma (Table 1) .
Administration of ICT2588 did not result in a significant increase in circulating levels of vWF at 24 hours over that detected in vehicle-treated controls (P = 0.6; Table 1 and Figure   6 ). In contrast, azademethylcolchicine at an equimolar dose caused a significant elevation in plasma vWF levels after 24 hours (P < 0.05; Table 1 and Figure 6 ). No increase in plasma vWF levels were detected following exposure to the chemotherapeutic agent doxorubicin ( Figure 6 ). Additionally, no delayed rise in vWF levels was observed with the prodrug ICT2588, as at 48 hours the plasma vWF concentration was not significantly different to vehicle treated control mice (P = 0.50; Table 1 ). 
Plasma concentration of vWF (IU/ml)
DISCUSSION
Drug-induced disruption of established tumor vasculature is a promising therapeutic strategy, with several colchicine based VDAs currently in late-stage development [11] [12] [13] .
However, the off-target toxicities of these agents, primarily against the cardiovascular system, has limited their clinical progression 17, 18 . We previously reported a therapeutic strategy to overcome the limitations outlined above, which exploits the therapeutic potential of VDAs and exploits the tumor phenotype. The therapeutic 'smartbomb', ICT2588, was designed to selectively deliver the VDA, azademethylcolchicine, to the tumor through activation by membrane-type MMPs (MT-MMPs) endopeptidases specifically located within the tumor microenvironment 5 .
ICT2588 illustrates how harnessing of the tumor degradome to convert an inactive 'smartbomb' into its active chemotherapeutic metabolite, has shown significant promise 5 .
Elevated expression of membrane-type MMPs (MT-MMPs) has been demonstrated in many tumor types, both preclinically and clinically 5, 25, 27, 30, 38 , with a direct relationship between genetic expression of MMP-14 (MT1-MMP) and its enzyme activity 38 , strongly supporting these endopeptidases as tumor-selective activators of therapeutics 5, 21, 38 . Our previous study demonstrated the viability for MMP-14 activated tumor 'smartbombs' and illustrated proofof-concept, using a human fibrosarcoma xenograft model known to express very high levels of MMP-14 5, 38 . Together with the pivotal role MMP-14 plays in tumor expansion and dissemination 26, 29, 30 , the implication is that this technology would be applicable In the present study we evaluated ICT2588 against azademethylcolchicine and combretastatin-A4-phosphate (CA4P), two systemically active VDA's. ICT2588 was threefold and seven-fold more active in terms of growth delay relative to azademethylcolchicine and CA4P respectively, indicating this tumor-activated molecule offers a benefit consistent with dose-exposure intensification previously reported for ICT2588 5 .
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The reduced systemic exposure offered by ICT2588 through tumor-selective activation effectively reduces the likelihood of cardiovascular toxicities commonly associated with VDA therapy 13, 17, 18 . Such an assumption is based on previous studies wherein levels of azademethylcolchicine were below the level of detection in the circulation or cardiac tissue following ICT2588 administration 5 . However, a lack of detectable active agent does not account for effects upon endothelial and cardiovascular function. Increased plasma levels of von Willebrand factor (vWF) is a validated biomarker indicative of systemic vascular dysfunction and predictive of acute cardiovascular events [34] [35] [36] . Importantly the absence of raised vWF following ICT2588 administration to mice suggests that our targeted VDA is not overtly cardiotoxic, a problem commonly associated with VDA therapy 13, 17, 18 . Post ICT2588 treatment, levels of vWF were no greater than observed with the antiproliferative agent doxorubicin. Although doxorubicin is identified with clinical cardiotoxicity, this is a consequence of cumulative chronic drug exposure 43 . Acute exposure to doxorubicin is not associated with cardiovascular events, as previously reported in a preclinical study of breast cancer therapy 37 . In summary these results support our previous study which shows that tumor-selective activation of ICT2588 is producing an increased therapeutic index, not only due to dose enhancement at the tumor site, but also because of reduced systemic toxicity.
In conclusion, the activity of ICT2588 against colorectal, lung, breast and prostate tumors supports its widespread therapeutic potential and activation in clinical tumors associated with MMP-14 expression. This, in combination with lower and evidential reduction in potential for inducing cardiovascular events provides strong justification for progression of ICT2588 as a tumor-selective VDA. 
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